Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and is the leading cause of death from infectious diseases worldwide, being considered a granulomatous infection. The quinoline molecules were chosen because they possess antifungal and antimicrobial properties, which are normally related to their biological activities, being a privileged structure in medicinal chemistry, capable of modulating multiple targets, including kinases. The target prediction revealed a strong association with vascular endothelial growth factor receptor 2 (KDR), with 1300 and 1447 similar compounds. This article shows the structural reactivity of the four derivatives of 1,4-dihydro-4-oxo-quinoline-3-carbohydrazide, evaluated through DFT calculations in vacuum and DMSO (B3LYP/6–311 + + G(d,p)), using the ORCA 5.04 program. In addition, this study also used computational approaches of virtual screening and ADMET prediction to evaluate pharmacokinetic properties. The analyses were performed using the softwares SwissADME, ADMETlab 3.0, admetSAR 3.0, pkCSM, Pred-hERG 5.0, StopTox, and ADMET Prediction Service—LMC, and involved the evaluation of oral bioavailability (0.55 for all compounds), intestinal permeability (Caco-2: −4.708 to −4.756), toxicity (non-toxic), and pharmacokinetic profile, selecting the compounds with the best characteristics for absorption and distribution. The results showed that the QNL1 and QNL3 derivatives were the most favorable due to high intestinal absorption (> 95%) and apparent permeability (Papp > 1.0 × 10 cm/s), showing potential as a future drug. In summary, the findings show these compounds as promising candidates for the treatment of tuberculosis, E. coli bacteria, and the fungus Aspergillus fumigatus.
M. Sales, Caroline Do Nascimento Gonçalves, Abraão Lucas Silva dos Santos et al.· Discover Chemistry· 0 citations
Chagas disease (CD), once found mainly in underdeveloped countries, is becoming a public health problem in the developed world. Although the drug benznidazole (BZN) is effective in the acute phase of the disease, it causes toxicity due to the formation of reactive substances resulting from presystemic metabolism, which have the ability to bind to DNA structures. This study conducts experimental tests with the epimastigote and trypomastigote species of the parasite, followed by drug–target interaction analyses through molecular docking against the enzymes trypanothione reductase, cruzain, and TcGAPDH, as well as pharmacokinetic prediction based on MPO analyses. In vitro tests revealed CPN4F’s significant efficacy in reducing host cell viability and inhibiting parasite growth. Molecular docking indicated CPN4F’s favorable energy ordering and superiority to BZN against the cruzain target (ΔG < −6.0 kcal mol–1), while molecular dynamics simulations showed that the complex remains stable in the 500 ns range. Pharmacokinetic estimates suggested high cell permeability (P app > 10 × 10–6 cm/s) but potential metabolic stability concerns (CLint,u > 8 mL/min/kg), showing good oral bioavailability, although with moderate metabolism. The CPN4F molecule demonstrates potent in vitro efficacy against Chagas disease, outperforming BZN in molecular docking studies targeting cruzain. Despite concerns about metabolic stability due to its high cell permeability and lipophilic nature, CPN4F exhibits low acute oral toxicity, highlighting its potential as a safe and effective treatment option.
J. Pinto, Francisco Nithael Melo Lucio, L. R. Ribeiro et al.· ACS Omega· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.